EDTUTC-4 New YorkLog in Sign up

LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
stockNASDAQ

At CloseOct 23, 2026 3:59:11 PM EDT

0.31USD-36.157%(-0.18)39,231,810

Pre-marketOct 23, 2026 9:29:30 AM EDT

0.3478USD-28.832%(-0.1409)

After-hoursOct 23, 2026 4:59:30 PM EDT

0.3234USD+3.654%(+0.0114)

LABT News

Day breaks

08:02 AM EDTLakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 ·

PR Newswire

08:02 AM EDTLakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds ·

PR Newswire

08:02 AM EDTLakewood-Amedex Biotherapeutics Announces Participation in October Conferences ·

PR Newswire

12:16 PM EDTLABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers ·

Zacks Small Cap Research

08:02 AM EDTLakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers ·

PR Newswire

08:02 AM EDTLakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers ·

PR Newswire

08:02 AM EDTLakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 ·

PR Newswire

08:13 AM EDTLakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers ·

PR Newswire